Prescription drug products should be granted automatic over-the-counter status once they have been on the market for 10 years or reached 100 million prescriptions, according to Sam Peltzman, a professor of economics at the Univeristy of Chicago.
The switch should be automatic, unless the Food and Drug Administration is able to demonstrate reasons why the product should remain prescription-only, Prof Peltzman told a conference in Washington, adding that studies of existing switch products have revealed "overwhelming benefits" to consumers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze